Kevin Culligan serves as the Managing Shareholder of the Firm’s New York Office and is a member of Maynard’s Intellectual Property Litigation and Intellectual Property Protection practice groups. He has focused his practice for 40 years on the litigation, trial, arbitration and appeal of intellectual property matters, concentrating primarily on patent, trade secret and unfair competition cases in the fields of pharmaceuticals, biosimilars, biotechnology, and financial services. Kevin also has extensive patent, trade secret, know-how and trademark licensing experience, and he counsels and represents clients in connection with IP strategy issues, joint development agreements and disputes, collaboration and license agreements and related disputes, supply agreements, IP transactions, and PTAB proceedings.
Clients and peers recognize Kevin internationally as a leading practitioner. LMG named Kevin a “Life Sciences Star” in 2019 and again in 2020 in the categories of General Patent Litigation, Patent Strategy & Management and Hatch-Waxman Patent Litigation. Managing Intellectual Property identified Kevin as a National and New York “IP Star” for 2020-2021. Best Lawyers in America has included Kevin every year since 2005 in the categories of Litigation: Intellectual Property and Litigation: Patent. Super Lawyers has identified Kevin as a “Top Rated Intellectual Property Litigation Attorney” in New York City every year since 2006. LMG named Kevin to its “Best of the Best USA Patent Litigators” in 2014 and 2016, and in 2014 identified Kevin as one of the 30 best patent litigators in the world in its “Best of the Best Patent Litigators Worldwide.”
Members of the financial services industry regard Kevin as a thought leader in patent litigation and IP licensing matters. Kevin served as the Chairperson of the last two (15th and 16th) annual summit meetings in New York focusing on Protecting Innovations in the Financial Services Industry.
Before joining Maynard, Culligan was a partner in Goodwin’s IP Litigation Group, Patent Litigation Practice, and FinTech Practice. He earned an A.B. in Biology from Colgate University in 1976 and a J.D. from Cornell Law School in 1980 and was a partner for many years at Fish & Neave before that patent litigation firm merged with another firm in 2005.